These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 24050286)

  • 21. Efficacy of amorolfine nail lacquer for the prophylaxis of onychomycosis over 3 years.
    Sigurgeirsson B; Olafsson JH; Steinsson JT; Kerrouche N; Sidou F
    J Eur Acad Dermatol Venereol; 2010 Aug; 24(8):910-5. PubMed ID: 20028447
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Onychomycosis: Current trends in diagnosis and treatment.
    Westerberg DP; Voyack MJ
    Am Fam Physician; 2013 Dec; 88(11):762-70. PubMed ID: 24364524
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treating onychomycosis.
    Rodgers P; Bassler M
    Am Fam Physician; 2001 Feb; 63(4):663-72, 677-8. PubMed ID: 11237081
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Laser Therapies for Onychomycosis in Japan].
    Kimura U; Suga Y
    Med Mycol J; 2018; 59(3):J45-J49. PubMed ID: 30175813
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Study of the efficacy and tolerability of oral terbinafine in the treatment of onychomycosis in renal transplant patients.
    Lee KH; Kim YS; Kim MS; Chung HS; Park K
    Transplant Proc; 1996 Jun; 28(3):1488-9. PubMed ID: 8658754
    [No Abstract]   [Full Text] [Related]  

  • 26. Laser and light therapy for onychomycosis: a systematic review.
    Ledon JA; Savas J; Franca K; Chacon A; Nouri K
    Lasers Med Sci; 2014 Mar; 29(2):823-9. PubMed ID: 23179307
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An open, randomized, comparative study of oral fluconazole, itraconazole and terbinafine therapy in onychomycosis.
    Arca E; Taştan HB; Akar A; Kurumlu Z; Gür AR
    J Dermatolog Treat; 2002 Mar; 13(1):3-9. PubMed ID: 12006131
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cumulative meta-analysis of systemic antifungal agents for the treatment of onychomycosis.
    Gupta AK; Ryder JE; Johnson AM
    Br J Dermatol; 2004 Mar; 150(3):537-44. PubMed ID: 15030339
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pulse itraconazole vs. continuous terbinafine for the treatment of dermatophyte toenail onychomycosis in patients with diabetes mellitus.
    Gupta AK; Gover MD; Lynde CW
    J Eur Acad Dermatol Venereol; 2006 Nov; 20(10):1188-93. PubMed ID: 17062029
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and efficacy of oral terbinafine in the treatment of onychomycosis: analysis of the elderly subgroup in Improving Results in ONychomycosis-Concomitant Lamisil and Debridement (IRON-CLAD), an open-label, randomized trial.
    Tavakkol A; Fellman S; Kianifard F
    Am J Geriatr Pharmacother; 2006 Mar; 4(1):1-13. PubMed ID: 16730616
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination of oral terbinafine and topical ciclopirox compared to oral terbinafine for the treatment of onychomycosis.
    Avner S; Nir N; Henri T
    J Dermatolog Treat; 2005; 16(5-6):327-30. PubMed ID: 16428154
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic potential of TDT 067 (terbinafine in Transfersome): a carrier-based dosage form of terbinafine for onychomycosis.
    Sigurgeirsson B; Ghannoum M
    Expert Opin Investig Drugs; 2012 Oct; 21(10):1549-62. PubMed ID: 22876754
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Topical amorolfine for 15 months combined with 12 weeks of oral terbinafine, a cost-effective treatment for onychomycosis.
    Baran R
    Br J Dermatol; 2001 Oct; 145 Suppl 60():15-9. PubMed ID: 11777260
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical trials of lasers for toenail onychomycosis: The implications of new regulatory guidance.
    Gupta AK; Foley KA; Daigle D
    J Dermatolog Treat; 2017 May; 28(3):264-270. PubMed ID: 27686529
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Toenail onychomycosis: current and future treatment options.
    Finch JJ; Warshaw EM
    Dermatol Ther; 2007; 20(1):31-46. PubMed ID: 17403258
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent updates in oral terbinafine: its use in onychomycosis and tinea capitis in the US.
    Van Duyn Graham L; Elewski BE
    Mycoses; 2011 Nov; 54(6):e679-85. PubMed ID: 21668517
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emerging therapies for the treatment of ungual onychomycosis.
    Kushwaha A; Murthy RN; Murthy SN; Elkeeb R; Hui X; Maibach HI
    Drug Dev Ind Pharm; 2015; 41(10):1575-81. PubMed ID: 25997365
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A multicentre, randomized, controlled study of the efficacy, safety and cost-effectiveness of a combination therapy with amorolfine nail lacquer and oral terbinafine compared with oral terbinafine alone for the treatment of onychomycosis with matrix involvement.
    Baran R; Sigurgeirsson B; de Berker D; Kaufmann R; Lecha M; Faergemann J; Kerrouche N; Sidou F
    Br J Dermatol; 2007 Jul; 157(1):149-57. PubMed ID: 17553051
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Topical antifungal drugs for the treatment of onychomycosis: an overview of current strategies for monotherapy and combination therapy.
    Baran R; Kaoukhov A
    J Eur Acad Dermatol Venereol; 2005 Jan; 19(1):21-9. PubMed ID: 15649187
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy of laser therapy combined with topical antifungal agents for onychomycosis: a systematic review and meta-analysis of randomised controlled trials.
    Zhang J; Lin P; Li J; Guo C; Zhai J; Zhang Y
    Lasers Med Sci; 2022 Aug; 37(6):2557-2569. PubMed ID: 35484440
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.